In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer/PerSeptive Biosystems: Hart-Scott-Rodino antitrust review of Perkin-Elmer's proposed $360 mil. acquisition of PerSeptive is extended as a result of a Department of Justice request for additional information related to the transaction. A definitive agreement for the deal was announced Aug. 25 ("The Gray Sheet" Sept. 1, p. 6). Both firms offer mass spectrometry products that enable lab technicians to analyze and sequence peptide and protein biomolecules; the firms maintain that their respective technologies are used in different phases of the drug discovery process. In addition to regulatory approval, the deal is contingent on a vote by PerSeptive shareholders, a meeting of which is slated for Dec. 4...
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.